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Abstract
Background High budget impact (BI) estimates of new drugs have led to decision-making challenges potentially resulting in 
restrictions in patient access. However, current BI predictions are rather inaccurate and short term. We therefore developed 
a new approach for BI prediction. Here, we describe the validation of our BI prediction approach using oncology drugs as 
a case study.
Methods We used Dutch population-level data to estimate BI where BI is defined as list price multiplied by volume. We 
included drugs in the antineoplastic agents ATC category which the European Medicines Agency (EMA) considered a New 
Active Substance and received EMA marketing authorization (MA) between 2000 and 2017. A mixed-effects model was 
used for prediction and included tumor site, orphan, first in class or conditional approval designation as covariates. Data 
from 2000 to 2012 were the training set. BI was predicted monthly from 0 to 45 months after MA. Cross-validation was 
performed using a rolling forecasting origin with e^|Ln(observed BI/predicted BI)| as outcome.
Results The training set and validation set included 25 and 44 products, respectively. Mean error, composed of all validation 
outcomes, was 2.94 (median 1.57). Errors are higher with less available data and at more future predictions. Highest errors 
occur without any prior data. From 10 months onward, error remains constant.
Conclusions The validation shows that the method can relatively accurately predict BI. For payers or policymakers, this 
approach can yield a valuable addition to current BI predictions due to its ease of use, independence of indications and abil-
ity to update predictions to the most recent data.
Keywords Budget impact · Oncology · Medicines · Budget impact estimation · Prediction modeling · Validation study
JEL Classification I180 · I130 · I100
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Introduction
In recent years, the prices of new drugs, for example in 
oncology, have increased considerably [1]. Combined with 
the increasing number of annual oncology approvals and 
expanding indications, drug treatment costs in this field have 
increased sharply. This has resulted in significant macrolevel 
budget impact (BI) discussions [1]. High BI estimations and 
the potential of a negative impact on affordability and patient 
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access have, unsurprisingly, led to decision-making chal-
lenges and debate [2–5].
In many jurisdictions, patient access is governed by 
institutional payers or national reimbursement agencies [6]. 
When facing budgetary constraints, as is the case in, for 
example, England, (additional) spending on one drug must 
be covered by disinvesting in other interventions or services 
[7, 8]. Budgetary limitations and budgeting policies cause 
payers or reimbursement agencies to limit access to high-
priced pharmaceuticals and/or products with a high BI and 
therefore burden to healthcare budgets and society [9].
It is a trend that more new drugs gain marketing approval 
with limited evidence packages [10]. The orphan designation 
and conditional approval legislation might have been suc-
cessful in increasing the therapeutic options in some disease 
areas, but it does have adverse effects on payers: much more 
uncertainty regarding clinical and cost-effectiveness and BI 
[11–15]. The combination of high price and high uncertainty 
in (cost-)effectiveness as well as the potential population 
size and therefore budget impact poses the greatest risk to 
payers or budget holders. In this study, we will focus on the 
budget impact as source of uncertainty in reimbursement 
decision making. According to a review by van de Vooren 
et al., many published budget impact analyses (BIAs) still 
fail to reach an acceptable quality [16]. Many BIAs are short 
term (1 year), quite subjective or based on expert opinion 
and determined by estimations of population size and even-
tual treatment regimen [17, 18]. If the general methodologi-
cal quality of BI analyses is indeed low, one would expect 
the predictive accuracy of these analyses to also be low.
Broder et al., who evaluated BI forecasts of US drug 
launches between September 1, 2010, and September 1, 
2015, concluded that the average predicted BI was 5.5 times 
the observed BI. Cha et al. concluded that 60% of the drug 
forecasts were off by more than 40% [17, 18]. Keeping et al. 
recently wrote that BI estimates used by Welsh payers that 
were specifically produced to inform access decisions were 
off by more than 40% in 80% of the cases [19]. We believe 
that these findings illustrate that the methodological quality 
as well as the predictive accuracy of current BIAs can be 
considered as low.
Not only are these estimations insufficient in provid-
ing adequate clarity on the costs of a new drug, but they 
also fail to quantify the uncertainty that is associated with 
these predictions. In other words, the current point esti-
mates or ranges given are not based on an underlying prob-
ability distribution and thus provide insufficient insight 
into the possible range of financial outcomes. Especially 
given the concerns regarding accuracy and methodologi-
cal quality mentioned previously, insights into uncertainty 
surrounding BI estimates could prove to be a crucial step 
in increasing the use and validity of BIA. Consequently, 
noting that conducting (probabilistic) sensitivity analysis 
is now standard practice is cost-effectiveness analysis 
(CEA), allowing for proper sensitivity analysis in BIA 
could increase its validity.
Proper incorporation of (accurate) budget impact predic-
tions in reimbursement decisions is essential for ensuring 
patient access and affordability [1–4]. Therefore, we devel-
oped a new approach for BI predictions using population-
based drug volume data and a mixed-effects model aiming 
to improve prediction of future BI and quantification of 
uncertainty of the predicted BI. In this paper, we describe 
this BI prediction approach and the validation of this method 
using a Dutch perspective and using oncology drugs as a 
case study.
Methods
We used population-level data provided by FarmInform 
to estimate and validate BI [20]. These data contain the 
monthly BI as list price multiplied by volume (gener-
ated in the in- and outpatient setting) of all prescription 
drugs in the Netherlands from January 1, 2000, to October 
1, 2017. We denote these monthly products as BI data 
records. FarmInform cross-checks the data with Dutch 
patient-level PHARMO data to ensure generalizability 
[21, 22].
Products were selected using the following criteria: First, 
products should belong to the ‘antineoplastic agents’ (L01) 
ATC category. Second, products should have gained market-
ing authorization (MA) by the European Medicines Agency 
(EMA) between January 1, 2000, and October 1, 2017. 
Third, the European Public Assessment Report (EPAR) 
should state that the product received MA for an oncology 
indication [23]. Finally, the product should be designated 
as a ‘New Active Substance’ by the EMA [23]. Biosimilars 
were then excluded.
For all included products, the following characteris-
tics (at time of MA) were collected from the EPAR and/
or the European Commission Decision documents [23, 24]: 
orphan designation, conditional approval, MA under excep-
tional circumstances, the molecule type (e.g., small mol-
ecule, monoclonal antibody) and indication(s). MA under 
exceptional circumstances and conditional approval were 
then combined into one covariate denoted as ‘CE.’ Indica-
tions were subsequently categorized into cancer sites (e.g., 
breast, lung). We furthermore collected data on Food and 
Drug Administration (FDA) First in Class (FiC) designation 
which we derived from Eder et al. and FDA Novel Drug 
Approvals summaries [25, 26]. As we chose the perspective 
of individual drug products and not drug classes or patient 
populations, indication extensions or label changes of prod-
ucts were not included.
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We used a mixed-effects model for prediction. Model 
building and validation were performed in R for Windows 
using the nlme package [27, 28]. The dataset was split in 
a training set and a validation set based on the date of the 
monthly BI data record. The training set was used for con-
structing the mixed-effects model. The splitting point of the 
dataset for model building was set at 149 months, indicating 
that products with a BI data record prior to May 1, 2012, 
were selected as training set and products with a first BI 
data record after this date as validation set. Only the first 
45 months of BI records per drug was included as this is the 
period we aim to predict, denoted as t_max. The duration of 
the period for the training set was based on a proper balance 
between the number of products in the training set (n = 25) 
and an adequate number of months in the validation set. This 
adequate number of months of data in the validation set is 
needed to ensure the capture of a sufficiently large portion 
of the 45 months of data for a sufficient amount of validation 
set products (n = 44).
On the training set, model building was performed using 
forward stepwise selection (lowest Akaike information cri-
terion (AIC), p < 0.10). Interactions with the square root of 
time and time to the power 1–6 were included as a possible 
step to model time dependence. Only a single time interac-
tion per covariate was allowed.
As Shmueli stated, overfitting to training data is the big-
gest danger to generalizability of predictive models [29]. 
Moreover, it is explained that it is not required to explore 
the causal structure of variables as, in prediction models, 
predictor selection should be solely based on quality of the 
association between the predictor and response [29]. In order 
to limit risk of overfitting, we therefore did not force main 
effects of interactions to be included in the model. Due to 
right-skewed BI data, log transformed monthly BI (per low-
est AIC) was selected as dependent variable. Random effects 
were composed of a random intercept and a random slope 
for time per product, based on lowest AIC. The correlation 
structure was defined as autoregressive with an order of 1 
for time.
We then performed cross-validation. Let A be the vali-
dation set products, k be a single product selected from A 
and B be the resulting list of products in the training set 
which does not include k. A is constructed by selecting 
all products with a first BI record after May 1, 2012. Fig-
ure 1a–c provides a schematic overview of the validation 
procedure.
We simulated the effect of the monthly addition of new 
data, thereby modeling the passing of time and the influence 
this has on prediction by using a rolling forecasting origin. 
Hence, we adapt the training set to include all BI records on 
B just 1 month prior to the date of the first BI record of k. 
t_data represents the number of months of data available to 
model building and prediction, while t_pred indicates the 
month which is predicted. t_split governed the rolling fore-
cast and indicates the date at which the dataset is split into 
training and validation set.
The rolling forecasting origin, simulating passing time, 
used the following procedure: We set the initial cycle to start 
with zero BI records (t_data = 0) on k; t_split is set to the 
date of the first BI record of k. The training set is constructed 
to include all data until t_max (45 months) and t_split on B. 
The first 45 months (or less if k has a shorter MA period) of 
BI is then predicted for k (t_pred [1, t_max]) and compared 
with the observed BI data of k. In the next cycle, the first 
month of BI data will become available to the prediction 
model, so t_data = 1 and t_split are increased by 1 month. 
This implies that the first month of k’s records is added to 
the training set with B, governed by t_split, also advancing 
1 month. Prediction and comparison with observed data are 
then performed for k for t_pred [2, t_max]. The sequence is 
repeated for t_data [2, t_max − 1] and all products in A. This 
yields a total of 45 + 44 + … = 1035 time points.
To improve robustness, a validation is also performed on 
a training set with t_max = 42 which includes separate model 
building on this second training set. Subsequently, validation 
is performed with 42 months of BI prediction. The mean of 
the absolute individual predictions is then calculated for all 
k with t_data [0, t_max − 1] and t_pred [1, t_max] by tak-
ing the average of these data points for the 42 and 45 t_max 
runs. This produces the final prediction results for each k 
with a specific t_data and t_pred, denoted as the prediction 
samples.
The previous paragraphs have outlined the role of the 
training set (selection of model structure) and the valida-
tion set (accuracy of predictions, given the chosen model 
structure). Coefficients are, unlike the traditional notion of 
a training set, not governed by the initial training set, but 
are estimated for each prediction cycle, based on the avail-
able data (governed by t_split). We thus aim to validate a BI 
prediction approach which uses a fixed model structure and 
where the model is continuously retrained on future data. 
This validation approach is adopted as it represents the envi-
sioned implementation that can adapt to patient and market 
dynamics.
We capped predicted BI to a minimum or maximum value 
in order to limit the effect of potential outliers. The maxi-
mum predicted monthly BI was determined as two times the 
maximum monthly BI in the total dataset. The minimum 
monthly BI was set at an arbitrary €5000. The influence 
of limiting these values is explored by means of scenario 
analysis.
Equation 1 describes the calculation of the prediction 
error.
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The resulting ratio is symmetric for over- and underpre-
diction [30, 31]. The purpose of this transformation is to 
yield ratios that have a positive sign for over- as well as 
underprediction so that overpredictions do not cancel out 
underpredictions. An error of 2 should therefore be inter-
preted as, in case of observed BI of €10,000, a predicted 
BI of €5000 or €20,000. This error was calculated for each 
prediction sample, yielding error samples.
Results were compiled in three ways:
1. Aggregated per t_pred and t_data: Error samples are 
aggregated for each point in (t_pred, t_data).
2. Aggregated per t_data: Error samples are aggregated for 
each t_data.












In order to compare our results to the previously pub-
lished literature, we calculated the percentage of predictions 
that are between 40 and − 40% and between 100 and − 100% 
of the observed BI. Per prediction, this percentage is calcu-
lated using Eq. 2:
For all products, we investigated whether a reimbursement 
dossier was published by the Dutch Healthcare Institute (ZIN), 
the authority that performs Health Technology Assessment 
(HTA) and advises the Dutch Minister of Health on reimburse-
ment of new drugs. For the products with a reimbursement 
dossier, the amount of t_data on the date of publication of 
the report was recorded. Products can have t_data prior to 
the publication of the dossier when it has been available for 
another indication or through an alternative access scheme. In 
our envisioned implementation, the available t_data just prior 
(2)
percentage difference =
predicted BI − observed BI
observed BI
∗ 100
Fig. 1  Schematic presentation 
of the role and construction of 
the training and validation set, 
model development and the 
validation using a rolling fore-
cast origin. Arrows indicate BI 
record availability of a specific 
product. A dashed line indicates 
trimmed data, and a solid line 
indicates data included in a 
training set. Blue is assigned to 
training set products, orange to 
products that will be validated 
and green to the product that, 
in this example, is validated. * 
denotes data cutoff based on t_
max. # denotes data cutoff based 
on t_split. ¤ denotes the maxi-
mum value of t_pred which is 
identical to t_max. a Training 
set selection for model develop-
ment and resulting selection of 
validation products, b valida-
tion of the product depicted 
in green with t_data = 0. The 
t_split = November 1, 2013, 
similar to the first date of 
recorded BI for this particular 
product, c validation of the 
product depicted in green with 
t_data = 6. The t_split = May 
1, 2014
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to publication of the dossier would be used to make an up-to-
date BI prediction for the product in question.
Results
The training set used for model building contained 25 prod-
ucts with a mean of 33 months of data, and 15 and 16 prod-
ucts had data until t_max of 45 and 42 months, respectively. 
The validation set included 44 products with an average of 
27 months of data and 11 and 14 products having data until 
t_max of 45 and 42 months, respectively. This resulted in 
a total of 19,681 prediction and error samples. The prod-
ucts included in the datasets are displayed in Supplemental 
Table 1.
Fixed-effect selection for the 42 and 45 t_max models 
yielded the same fixed effects being time + time * CE, 
√(time) * Tumor site, molecule type, √(time) * FiC and 
√(time) * orphan designation. As random effects were not 
varied, both model structures are identical. The final model 
syntax was:
The results that are aggregated per t_pred and t_data are 
shown in Figs. 2 (mean) and 3 (median). These figures illus-
trate that the errors are higher in models with less available 
data (low t_data) and at predictions further in the future 
(a higher t_pred). The highest errors occur in the models 
without any prior data (t_data = 0) with a mean error ratio of 
6.37. From t_data > 10, the error seems to remain constant.
[lme(fixed = log(observed BI) ∼ Time + Time ∶ CE +Molecule_type
+ sqrt(Time) ∶ (Orphan_status + FiC_status + Tumor site), random
=∼ Time|Product, correlation = corARMA(p = 1, q = 0, form =∼ Time|Product)]
In Fig. 4, we present the results that are aggregated per 
t_data. The errors are clearly left-skewed and significantly 
reduce with increasing t_data as established using a linear 
regression on the individual samples (coefficient = − 0.117, 
se = 0.0039, p < 0.0001). The interquartile range (IQR) 
decreases with increasing t_data. Prediction performance 
increases substantially from increasing t_data from 0 to 5; 
Fig. 2  Mean error aggregated per future month (t_pred) and available 
data (t_data)
Fig. 3  Median error aggregated per future month (t_pred) and avail-
able data (t_data)
Fig. 4  Median error (orange) aggregated per t_pred, including error 
bars indicating the interquartile range and the regression line (blue). 
Coefficient = − 0.096, se = 0.0035, p < 0.0001
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from t_data > 10, model accuracy does not improve by add-
ing more data.
The unaggregated mean and median error for all sam-
ples are 2.94 (standard deviation (SD) = 5.64) and 1.57 
(interquartile range (IQR) = 1.42), respectively. The mean 
of Ln(observed BI/predicted BI), so without converting 
to absolute values, of all samples, depicted in Fig. 5, did 
significantly differ from 0 (t test: mean = 0.057, n = 19,681, 
95% CI = 0.043;0.070, p < 0.0001). In absolute terms, under-
prediction was significantly more likely than overprediction 
(exact binomial test, prob. underprediction = 0.515, 95% 
CI = 0.508; 0.522, p < 0.0001). Using Eq. 2, we calculated 
the percentage difference that can be compared with other 
literature. Of the 19,681 samples, 9,503 (48.3%) had a maxi-
mum percentage difference between 40 and − 40%. For the 
100% to − 100% range, this number was 15,915 (80.9%). 
Table 1 summarizes the main outcomes.
In the training set, three products did not have a reim-
bursement dossier and nine products did not have t_data at 
the time of publication of the dossier. For the 13 training set 
products with t_data, the median and mean months of t_data 
were 22 and 29.8 (sd = 32.1), respectively. In the validation 
set, 28 products did not have a dossier and 10 products (with 
a dossier) had 0 t_data. The six products with a dossier and 
t_data > 0 had a median and mean t_data of 12.5 and 16.5 
(sd = 11.8), respectively.
Scenario analyses
We explored the influence of limiting predictions to a 
minimum (< €5000) and maximum (> 2 times maximum 
recorded BI) on the outcomes by adopting scenarios where 
(1) only minimum values were adjusted, (2) only maximum 
values were adjusted and (3) no predictions were adjusted. 
In the base case analysis, on a total of 19,681 samples, 930 
minimum and 44 maximum values were adjusted. The out-
comes are presented in Supplementary Tables 2–4.
These results indicate that not limiting minimum values 
has a profound negative influence on model performance as, 
presented in Supplementary Table 3, but mean unaggregated 
error increases to 8.00 with a very large sd of 358.74. On the 
contrary, not limiting maximum only has a minor impact, as 
Table 1 and Supplementary Table 2 yield nearly identical 
results. As only the more extreme values are concerned, it 
is logical that the median figures (Supplemental Tables 2–4) 
are very similar to the median base case results.
Discussion
Our prediction model was constructed using a mixed-effects 
approach with a training set of 25 oncology products. The 
validation of this prediction model using a training set of 44 
products yielded 19,681 samples and resulted in an overall 
mean error of 2.94. This error is higher when available data 
are more limited and when predicting further into the future. 
The decline in error with increasing available data seems 
to halt, at a median error of ± 1.5, around 5–10 months of 
data. This indicates that relatively accurate predictions can 
be generated with 5–10 months of data. There is a slight but 
significant higher probability of underprediction versus over-
prediction. The percentage of predictions that were within 
40% to − 40% and within 100% to − 100% of observed BI 
were 48.3% and 80.9%, respectively.
We envision the following implementation: Initially, a 
model structure would be selected and validated using the 
procedures herein described. Then, with an estimate of the 
model performance, BI predictions, using up-to-date data of 
all other products based on which the model is trained, can 
then easily be generated for a new product (with or without 
prior BI data of that product). The validation results can 
yield insights into the expected accuracy for this new drug 
for a specific future month (t_pred) and a specific amount of 
available BI data (t_data). At some future moment, of which 
the specifics are beyond the scope of this paper, continuous 
Fig. 5  Histogram of the individual outcomes. Outcomes calculated as 
Ln(observed BI/predicted BI) (blue) and the theoretical normal distri-
bution (orange)
Table 1  Main validation outcomes
Outcome Value
Mean error, aggregated per t_data and t_pred (SD) 3.01 (2.24)
Mean error, not aggregated (SD) 2.94 (5.63)
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model retraining on new data will probably not suffice as the 
validation set at that time will not be representative of the 
training set on which the model structure was developed. In 
that case, model selection and validation would have to be 
redone. This would also be applicable to using our method-
ology in other jurisdictions or geographic areas, for predict-
ing different or entirely new drug classes or when adapting 
to changes in regulatory systems.
Our BI predictions are quite constant and rather accurate 
from 10 months of available data as the median aggregated 
error from 10 months onward ranges from 1.20 to 1.42. As 
the error is highest with little available data, one could say 
that our approach is not useful for BI predictions when these 
predictions are part of a reimbursement dossier in a ‘closed’ 
reimbursement system, indicating reimbursement for new 
drugs is only available after an HTA decision. However, 
various countries have (partly) open systems (e.g., Germany, 
the Netherlands) wherein HTA dossiers become available 
after the drug is already available and in use. In our dataset, 
we have shown that 50% of the products have a substantial 
amount of data available at the date of publication of the 
reimbursement dossier. It is therefore very probable that, at 
least for open reimbursement systems, a sufficient amount 
of BI data will in many cases be available to overcome the 
high errors associated with having less than 5–10 months of 
available data for prediction.
When extending the use of BIA beyond the initial reim-
bursement decision to a more dynamic drug life cycle 
approach, for example as part of managed entry agreements, 
available BI data will keep increasing and will therefore 
rapidly be sufficient for achieving our reported maximum 
predictive accuracy [32].
Cha et al. analyzed the accuracy of peak sales forecasts 
produced by the so-called sell-side analysts [17]. They cat-
egorized the forecasts in categories of percentage difference 
between forecasts and observed peak sales. Their highest 
deviation categories were < − 80% (n = 7/260) and > 160% 
(n = 57/260) and found a median error of 4%. They do state 
that most forecasts are poor and that the variance is high, 
but the 4% median error does not give clear insight into 
forecast error as overestimations can cancel out underestima-
tions (i.e., their error is not symmetric) and as the maximum 
error is limited (− 80% and 160%). We have partly applied 
the methodology used by Cha et al. to our dataset by also 
limiting the maximum error and by not making the error 
symmetric. Using this method, our median error is − 3%, a 
major difference between our unaggregated and symmetric 
median error of 1.54 (154%). Cha and colleagues further-
more state that more than 60% of the forecasts were off by 
more than 40%, whereas in our analysis 51.7% of estima-
tions had a higher deviation than 40%.
Broder et al. published a review of the bias in BI predic-
tions of new drugs [18]. They used a US perspective and 
included formal, more scientific, BI predictions as well 
as informal predictions that are aimed at projecting share 
prices. All estimates were made less than 12 months before 
launch, and nearly all estimates were for just the first year. 
Mean predicted BI in the sample was 5.5 times the observed 
BI. When excluding the informal predictions, the average 
overestimation is 5.6 times the observed BI. These values 
are asymmetric representations of under- and overprediction 
(i.e., the value is attenuated toward 1 due to underpredictions 
that have a value between 0 and 1) and are still higher than 
our (symmetric) mean error. Only 20% of the predictions 
were within 40% of the observed usage, compared to 48,3% 
for our model [19]. If we then relate to the differing lengths 
of forecast period (i.e., t_pred) of 1 year for Broder et al. and 
45 months for our study, we could argue that our predictions 
seem to have better accuracy while providing more future 
predictions.
Keeping et al. investigated BI estimates that were part 
of pharmaceutical company submissions and compared 
them to the observed expenditure [19]. These company 
submissions were issued to the All Wales Medicines Strat-
egy Group (AWMSG) for reimbursement decision making. 
The AWMSG is the institution that appraises clinical and 
cost-effectiveness of new medicines being considered for 
the National Health Service prescribing in Wales (UK). A 
total of 49 medicines were included, and the percentage 
of predictions in the 40% and 100% range was 20.4% and 
53.1%, respectively. Our model achieved 48.3% and 80.9% 
on these respective accuracy markers. Of the 49 products 
Keeping and colleagues included, only 3–6 (depending on 
the definition) had an oncological indication which is there-
fore quite different from our oncology cohort. Still, as the 
BI estimates investigated by Keeping et al. are those used by 
payers to inform decision making, the work of Keeping et al. 
is very relevant. Even though our results are not directly 
comparable, we still argue that our superior performance in 
the 40% and 100% range metric is a rather clear indicator 
that our method has the potential to be superior to current BI 
estimates used by payers and decision makers.
Our BI prediction approach potentially has several advan-
tages over current BI estimation procedures. Firstly, our 
methodology is independent of indication extensions. Of 
course, additional indications do have an influence on BI 
and possibly on the accuracy of the predictions. We, how-
ever, chose to not include indication expansions as a predic-
tor variable as this would be rather laborious to perform in 
practice for a large group of products. Unlike current Dutch 
Reimbursement authority (‘National Health Care Institute’) 
BI predictions, our model intrinsically adjusts for possible 
changes in indications as we apply a drug perspective irre-
spective of indication.
Another potential advantage of our BI prediction 
approach is the ease and speed with which BI predictions 
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can be constructed. Updating the data, possibly perform-
ing a separate validation and then performing the predic-
tion for a new drug would be a matter of hours, whereas 
the current guidelines call for a much more time consuming 
endeavor [33, 34]. This advantage is especially profound if 
you include the option of semiautomatically updating the 
predictions as time passes and more data become available.
Finally, our model results yields predictions with a poten-
tially quantifiable amount of uncertainty as the distribution 
of error is known and can be adjusted for the amount of data 
already available (t_data) and the number of future months 
(t_pred). This is hardly possible with current BI predictions 
that produce point estimates. Our approach could therefore 
serve as a basis for more profound modeling of uncertainty 
around BI predictions.
Our study has various limitations. First, we have only 
validated our model for a rather specific set of products and 
characteristics. Future products, for example novel advanced 
therapy medicinal products, are not validated and are there-
fore probably not accurately predictable by our current 
model. As is, however, described above, the dataset can be 
updated to future states and a new validation can then be 
done rather easily in order to accommodate new drug classes 
and/or characteristics.
Second, we have no direct comparison of our results to 
the current BI estimations used in practice. As our model 
is based on Dutch data, it would be very insightful to com-
pare our results with observed BI predictions published by 
the Dutch Reimbursement authority. In light of the Broder 
et al., Cha et al. and Keeping et al. findings, our prediction 
accuracy appears to be superior.
Third, we have capped minimum and maximum BI pre-
dictions which to an extent impacted results. Our explicit 
assumption of a predicted maximum of two times the max-
imum monthly BI in the total dataset has no evidentiary 
basis. Potentially worse, there were records in the dataset 
with monthly BI below the minimum monthly amount of 
€5000. In other words, it is quite probable that we overes-
timate certain products with monthly BI below €5000. We, 
however, believe that these caps are justified as one of our 
main aims is to provide payers with better BI predictions. 
A difference between €5000 and €50 yields 4.6 log units of 
deviation, but this difference, in absolute terms, is probably 
not very relevant to payers.
We have explored the influence of these value restrictions 
through scenario analyses. These have clearly indicated that 
only limiting the lower values to €5000 and not restrict-
ing maximum values delivers a nearly identical predictive 
performance. We thus believe that these limits improve the 
relevance of our outcomes as prediction errors that are irrel-
evant on a macrolevel, e.g., €5 versus €5000 per month, 
are omitted. The high-level caps are implemented as some 
modeling scenarios yielded predictions that were irrationally 
high (for example, higher than the entire Dutch healthcare 
budget) and can therefore be identified by potential users 
of this method. In order to limit these scenarios to realistic 
figures, the factor two limit was imposed.
Fourth, we understand that alternative potentially more 
advanced validation techniques have been developed. In 
order to construct a methodology that is suitable for inform-
ing decision making, the method has to be interpretable and 
transparent. We therefore abstain from adding more com-
plexity to the current model in order to also keep it as practi-
cal as possible.
Still, we believe that, based on our validation, we have 
developed a valid method to predict BI. We were able to 
compare our results with three independent studies using 
a metric that describes the number of predictions that are 
within 40% to − 40% and 100% to − 100% of the observed 
BI. Our model was superior to all these three studies, and 
in particular, the study of Keeping et al. is important in this 
regard as they investigated the accuracy of BI predictions 
used by payers for reimbursement decision making.
Conclusions
The herein presented BI prediction approach can be used to 
develop models that can provide improved predictive accu-
racy compared to the current practice of conducting BIA. 
Additionally, our data-driven approach would allow for a 
more dynamic, life cycle approach to predicting and manag-
ing BI of drugs. To conclude, we think that our approach can 
be a valuable addition to BI predictions due to its potential 
for increased accuracy, independence of indications and abil-
ity to keep updating the predictions to the most recent data.
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